You're signed outSign in or to get full access.
About
Noelle Hutchins, PhD, is a Senior Associate at Omega Funds in Boston, where she focuses on private company investments within the biotechnology sector. Her primary investment emphasis is on oncology and inflammatory disorders, supporting the firm's mission to back innovative life sciences ventures. In her current role, she contributes to all stages of the investment lifecycle, from due diligence through deal execution and portfolio company support.
Dr. Hutchins serves as a Board Observer at Endeavor Biomedicines, underscoring her active involvement in portfolio company strategy and value creation within Omega Funds’ focus areas. Prior to joining Omega Funds in 2020, she advised and led scientific strategy for an emerging American Heart Association venture, consulted for TreMonti (commercial strategy, market analysis, licensing), and mentored science-focused entrepreneurs as an angel investor with Pipeline Angels.
She holds a PhD in Immunology from Brown University and a Bachelor of Science in Biology from the University of North Carolina at Chapel Hill. Her strong scientific background and venture expertise position her as a valuable contributor to identifying and advancing early-stage biotech investments, particularly in oncology and immunology.
Career History
| Organization | Role | Date Range | Details |
|---|---|---|---|
| Omega Funds | Senior Associate | Oct 2023 to Present | — |
| Omega Funds | Biotech VC Investor | Unknown to Present | — |
| Endeavor Biomedicines | Board Observer | Jun 2022 to Present | — |
| Omega Funds | Associate | Oct 2020 to Oct 2023 | — |
| Pipeline Angels | Member | Oct 2019 to Jan 2023 | Pipeline Angels is changing the face of angel investing and creating capital for women and non-binary femme social entrepreneurs.
Members serve as the friends and family round for entrepreneurs who m... |
| TreMonti Consulting | Life Science Consultant | Dec 2015 to Oct 2020 | Evaluated and determined the commercial suitability and intellectual property of 60+ early-stage biomedical technologies for investment and out-licensing opportunities |
| American Heart Association | Ideation Lead, Emerging Strategies and Ventures | Dec 2018 to Jul 2020 | — |
| American Heart Association | Science and Medicine Advisor | Nov 2016 to Dec 2018 | — |
| UT Southwestern Medical Center | Postdoctoral Research Scientist | Jan 2014 to May 2016 | Center for the Genetics of Host Defense |
| Rhode Island Hospital | Postdoctoral Research Scientist | Jul 2013 to Jun 2014 | Department of Surgery, Division of Surgical Research |
| Brown University | Graduate Student | Sep 2007 to May 2013 | Department of Surgery, Division of Surgical Research (Pathobiology Graduate Program) |
| Scynexis | Advanced Scientist | Jan 2007 to Sep 2007 | Animal Health Division |
| GlaxoSmithKline | Scientist | May 2006 to Jan 2007 | Department of Gene Expression and Protein Biochemistry (GEPB) |
| Mayo Clinic | Post-baccalaureate Student (Research Assistant) | May 2004 to Jan 2006 | Virology & Gene Therapy; Department of Molecular Medicine |
| University of North Carolina at Chapel Hill | Undergraduate Research Assistant | Jan 2002 to Jan 2004 | Department of Genetics
Lineberger Cancer Center |
| Leadership Alliance | Summer Undergraduate Research Fellow | Jun 2002 to Aug 2002 | Department of Pathology and Laboratory Medicine; VA Hospital
Pulmonary Vascular Biology Laboratory |
Education
Brown University
2007 — 2013
University of North Carolina at Chapel Hill
2000 — 2004
Others at Omega Fund Management, LLC (1)
| Name | Role | Location |
|---|---|---|
 | Partner | United States |
